Recombinant Anti-C5a antibody [EPR19699-24] (ab202039)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR19699-24] to C5a
- Suitable for: WB, IP
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-C5a antibody [EPR19699-24]
See all C5a primary antibodies -
Description
Rabbit monoclonal [EPR19699-24] to C5a -
Host species
Rabbit -
Tested applications
Suitable for: WB, IPmore details
Unsuitable for: IHC-P -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Human serum. IP: Human serum.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: PBS, 0.05% BSA, 40% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR19699-24 -
Isotype
IgG
Associated products
-
Alternative Versions
-
Compatible Secondaries
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab202039 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000.
|
|
IP |
1/30.
|
Notes |
---|
WB
1/1000. |
IP
1/30. |
Target
-
Relevance
Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation. -
Database links
- Entrez Gene: 727 Human
- SwissProt: P01031 Human
Images
-
Anti-C5a antibody [EPR19699-24] (ab202039) at 1/1000 dilution + Human serum at 20 µg
Secondary
VeriBlot for IP Detection Reagent (HRP) (ab131366) at 1/1000 dilution
Exposure time: 3 minutesC5 is cleaved into C5α and C5β and this antibody recognizes the C5α. The molecular weight observed is consistent with what has been described in the literature (PMID: 23401592)
-
C5a was immunoprecipitated from 0.35 mg human serum 10μg with ab202039 at 1/30 dilution (2μg in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab202039 at 1/2000 dilution (0.26 μg/ml). VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/10,000 dilution.
Lane 1: Human serum 10μg.
Lane 2: ab202039 IP in human serum.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab202039 in human serum.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 10 seconds.
This antibody recognizes C5a.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (2)
ab202039 has been referenced in 2 publications.
- Qin R et al. α2,6-Sialylation Is Upregulated in Severe COVID-19, Implicating the Complement Cascade. ACS Infect Dis 8:2348-2361 (2022). PubMed: 36219583
- Huang Z et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting complement activation and upregulation of miR-499. Exp Ther Med 22:684 (2021). PubMed: 33986849